In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more. Read the full coverage here: Evaluate headache characteristics to classify as migraine FDA grants breakthrough device designation for brain implant technology New genetic engineering company aims to develop neuroactive compounds from plants, fungi Angiotensin receptor blocker therapy associated with decreased incidence of epilepsy Theranica announces positive results from clinical trial for migraine treatment device References: Diamond M. Migraine, chronic migraine and medication overuse headache: Where are we today? Presented at: PAINWeek; Sept. 6-9, 2022; Las Vegas Doege C, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3413. Press Release. Press Release Press Release

Ver todos los episodios